Bone Biologics Corporation (BBLG)
Nasdaq · Healthcare · Biotechnology
$0.4852+2.06%as of Oct 6, 2026, 1:35 AM ET
- Market cap
- $1.3M
- 52-week range
- $0.428 – $2.79
- 52-week change
- −81.66%
- EPS (trailing)
- −$1.37
Fiscal year to Dec 2025
- Net income
- −$3.1M
- Diluted EPS
- −$2.65
From the company’s annual report on SEC EDGAR.
About Bone Biologics Corporation
Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein in the United States. Its lead product is NELL-1/DBM medical device, an osteopromotive recombinant protein, which provides target specific control over bone regeneration. The company also develops NB1, a NELL-1/DBM fusion device for use in lumbar spinal fusion, as well as spine implants, non-union trauma cases, and osteoporosis applications. It serves spine surgeons and patients with a skeletal bone defect or bone-related condition in their spine. The company has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion by local administration, osteoporosis, and trauma applications. Bone Biologics Corporation was founded in 2004 and is headquartered in Burlington, Massachusetts.
Headquarters: Burlington, United States · 2 employees · bonebiologics.com